Jim Cramer on Merck & Co.: “If We’re Really Going Into an Oil Shock-Induced Slowdown, I Think This One’s Likely an Outperformer””
View original at finance.yahoo.comJim Cramer on Merck & Co.: “If We’re Really Going Into an Oil Shock-Induced Slowdown, I Think This One’s Likely an Outperformer”” Jim Cramer reviewed Merck & Co., Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Merck is a lot based on Keytruda, an amazing oncological drug
60% confidenceIf we're really going into an oil shock-induced slowdown, Merck is likely an outperformer
60% confidenceMoney managers are happily accumulating Merck shares
60% confidenceMerck is acquiring an exciting potential treatment for chronic myeloid leukemia
60% confidenceThe market lapped up the acquisition news despite the target having no earnings
60% confidenceThe breakout above the 50-day moving average is very bullish
60% confidenceMerck has good money flow and Chaikin Money Flow is in very bullish territory
60% confidenceMerck stock could run all the way to $130 before year-end
60% confidenceInvestors should wait for the next pullback entry point in Merck
60% confidenceCertain AI stocks offer greater upside potential and carry less downside risk than Merck
60% confidenceRecent sell-offs of about 3 to 8% have been ideal entry points in Merck
60% confidence
Data points we hold from this source
| Merck & Co., Inc. · stock return | 39 percent |